

## Two New Cytotoxic Biphenyls from the Roots of *Incarvillea arguta*


by Jian-Jun Fu<sup>a</sup>), Hui-Zi Jin<sup>a</sup>), Yun-Heng Shen<sup>b</sup>), Jiang-Jiang Qin<sup>a</sup>), Yan Wang<sup>a</sup>), Ying Huang<sup>a</sup>), Qi Zeng<sup>a</sup>), Shi-Kai Yan<sup>a</sup>), and Wei-Dong Zhang<sup>\*a</sup>)<sup>b</sup>)

<sup>a</sup>) School of Pharmacy, Shanghai Jiaotong University, Shanghai 200240, P. R. China

<sup>b</sup>) Department of Phytochemistry, Second Military Medical University, Shanghai 200433, P. R. China  
(phone: +86-21-25070386; fax: +86-21-25070386; e-mail: wdzhangy@hotmail.com)

Two novel biphenyls, named incargutines A (**1**) and B (**2**), were isolated from the roots of *Incarvillea arguta*, and the structures were elucidated by detailed spectroscopic analysis, including HR-ESI-MS data and 2D-NMR spectroscopy. Compounds **1** and **2** contain an unprecedented C-atom skeleton, namely a 4-methylbiphenyl unit fused with a 7-methylcyclopentane unit at C(2) and C(3) (*i.e.*, a 1,7-dimethyl-4-phenylindane skeleton). The cytotoxicity of **1** and **2** was evaluated with four tumor cell lines, A549, LOVO, CEM, and MDA-MB-435 (MDA), by an MTT assay.

**Introduction.** – *Incarvillea arguta* (Bignoniaceae) mainly grows in the southwest area of China at an altitude of 1400–2700 m. It has been widely used as a herbal medicine of Yi nationality (known as ‘Wabuyou’) to treat hepatitis and diarrhea in China [1]. A number of ceramides, triterpenes, monoterpene alkaloids, and flavones have been reported from *I. arguta* [2–6]. Further investigation of this plant led us to isolate two novel biphenyls **1** and **2** with an unprecedented C<sub>17</sub> skeleton of the 4,7-dimethyl-1-phenylcyclopenta[*c*]benzene type (*i.e.*, of the 1,7-dimethyl-4-phenylindane type). To the best of our knowledge, this is the first example of a biphenyl natural product fused with a cyclopentane moiety at C(2) and C(3). We report on the isolation and structure elucidation of these novel biphenyls through extensive spectroscopic analysis and on their antitumor activities *in vitro*.



**Results and Discussion.** – The dried roots of *I. arguta* (24.9 kg) were chopped and percolated with 80% EtOH (4 × 50 l) at room temperature. The solvent was evaporated to give a crude extract (5.2 kg). The extract was taken up in 15 l of H<sub>2</sub>O and the resulting suspension acidified to pH 2 with H<sub>2</sub>SO<sub>4</sub> solution and filtered. The filtrate was basified to pH 10 with NaHCO<sub>3</sub> solution and then extracted with CHCl<sub>3</sub>.

<sup>1</sup>) Arbitrary atom numbering; for systematic names, see *Exper. Part*.


The  $\text{CHCl}_3$  extract (93 g) was separated by column chromatography (silica gel) and prep. HPLC to yield **1** (3.2 mg) and **2** (16.0 mg).

Incargutine A<sup>1</sup> (**1**) was obtained as a yellow oil. The molecular formula was determined as  $\text{C}_{17}\text{H}_{16}\text{O}_2$  by HR-ESI-MS ( $m/z$  251.1074 ( $[M - \text{H}]^-$ ,  $\text{C}_{17}\text{H}_{15}\text{O}_2^-$ ). The  $^{13}\text{C}$ -NMR and DEPT spectra of **1** showed 19 C-atoms, including one Me, two  $\text{CH}_2$ , seven CH, and one CHO group, and six quaternary aromatic C-atoms (Table 1). There were two sets of mutually coupled H-atoms in the aromatic region of the  $^1\text{H}$ -NMR spectrum of **1**: the one at  $\delta(\text{H})$  7.69 ( $d, J = 7.8$  Hz) and 7.24 ( $d, J = 7.8$  Hz) indicated a 1,2,3,4-tetrasubstituted benzene moiety, and the other one at  $\delta(\text{H})$  7.30 ( $d, J = 8.6$  Hz, H-C(2'), H-C(6')) and 6.92 ( $d, J = 8.6$  Hz, H-C(3'), H-C(5')) indicated a 1',4'-disubstituted benzene ring. In the HSQC spectrum of **1**, the signals at  $\delta(\text{H})$  10.18 ( $s$ ) correlated with the signal at  $\delta(\text{C})$  192.5 (C(10)). The CHO group of **1** was located at C(4) due to the HMBC cross-peaks H-C(10)/C(4) and C(5), and H-C(5)/C(4) and C(10) (Fig. 1), and the NOESY cross-peak H-C(10)/H-C(5). The analysis of the NOESY data is based on a 3D structure generated by molecular modeling (ChemOffice2006 Chem3D Ultra 10.0) with MM2 force-field calculations for energy minimization (Fig. 2).

Table 1.  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Data of **1** and **2**<sup>1</sup>. At 400/100 MHz, resp., in  $\text{CDCl}_3$ ;  $\delta$  in ppm,  $J$  in Hz.

<b>1</b>		<b>2</b>	
	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{C})$
C(1)		144.3	138.8
C(2)		131.0	132.2
C(3)		148.4	146.9
C(4)		146.4	141.9
H-C(5)	7.69 ( $d, J = 7.8$ )	129.8	7.36 ( $d, J = 7.8$ )
H-C(6)	7.24 ( $d, J = 7.8$ )	128.4	7.07 ( $d, J = 7.8$ )
H-C(7)	3.55–3.62 ( $m$ )	37.8	3.53–3.58 ( $m$ )
$\text{CH}_2$ (8)	2.31–2.35 ( $m$ ), 1.77–1.80 ( $m$ )	33.4	2.26–2.29 ( $m$ ), 1.67–1.71 ( $m$ )
$\text{CH}_2$ (9)	3.31–3.37 ( $m$ )	29.9	2.95–2.99 ( $m$ )
H-C(10)	10.18 ( $s$ )	192.5	5.41 ( $s$ )
Me(11)	0.80 ( $d, J = 7.0$ )	19.8	0.80 ( $d, J = 6.9$ )
Me(12)			3.37 ( $s$ )
Me(13)			3.37 ( $s$ )
C(1')		132.9	133.5
H-C(2')	7.30 ( $d, J = 8.6$ )	129.7	7.24 ( $d, J = 8.5$ )
H-C(3')	6.92 ( $d, J = 8.6$ )	115.4	6.87 ( $d, J = 8.5$ )
C(4')		155.6	155.4
H-C(5')	6.92 ( $d, J = 8.6$ )	115.4	6.87 ( $d, J = 8.5$ )
H-C(6')	7.30 ( $d, J = 8.6$ )	129.7	7.24 ( $d, J = 8.5$ )

The  $^1\text{H}$ -NMR signals of **1** at  $\delta(\text{H})$  3.55–3.62 ( $m$ ), 2.31–2.35 ( $m$ ), 1.77–1.80 ( $m$ ), 3.31–3.37 ( $m$ , 2 H), and 0.80 ( $d, J = 7.0$  Hz) correlated with the  $^{13}\text{C}$ -NMR signals at  $\delta(\text{C})$  37.8 (C(7)), 33.4 (C(8)), 33.4 (C(8)), 29.9 (C(9)), and 19.8 (C(11)), respectively, in the HSQC spectrum. Furthermore, the HMBC cross-peaks H-C(7)/C(3), C(4), C(8), C(9), and C(11),  $\text{H}_a$ -C(8) and  $\text{H}_b$ -C(8)/C(7), C(9), and C(11),  $\text{H}_a$ -C(9) and  $\text{H}_b$ -C(9)/C(2), C(3), C(4), C(7), and C(8), and Me(11)/C(3), C(7), and C(8),



$^1\text{H}, ^1\text{H}$ -COSY: — HMBC: H  $\dashrightarrow$  C Fig. 1. Selected 2D-NMR correlations for incargutine A (**1**)<sup>1</sup>




Fig. 2. Selected NOE correlations for incargutine A (**1**)

suggested the presence of a 7-methylcyclopentane unit fused with an arene ring at C(2) and C(3) in the structure of **1**. The IR spectrum revealed the presence of an OH group by the absorption at  $3370\text{ cm}^{-1}$ , and the OH substituent at C(4') ( $\delta(\text{C})$  155.6) was deduced from its chemical shift and the molecular formula. The specific rotation of **1** was positive; thus the structure of **1** was elucidated as (+)-4'-hydroxy-7-methylcyclopenta[*c*]biphenyl-4-carboxaldehyde with as yet unknown absolute configuration.

Incargutine B<sup>1</sup>) (**2**) was obtained as a yellow oil. The molecular formula was determined as  $\text{C}_{19}\text{H}_{22}\text{O}_3$  by HR-ESI-MS ( $m/z$  321.1466 ( $[M + \text{Na}]^+$ ,  $\text{C}_{19}\text{H}_{22}\text{NaO}_3^+$ ). The NMR data (Table 1) were very similar to those of **1**, but two additional MeO signals at  $\delta(\text{H})$  3.37 (s, Me(12), Me(13)) and  $\delta(\text{C})$  53.2 (C(12), C(13)) were present instead of the CHO signals of **1**. These MeO groups were placed at C(10) ( $\delta(\text{C})$  102.7) on the basis of their HMBC with C(10). The remaining 2D-NMR ( $^1\text{H}, ^1\text{H}$ -COSY, HSQC, HMBC, and NOESY) data were identical to those of **1**. The specific rotation of **2** was positive; thus the structure of **2** was elucidated as (+)-12,13-dimethoxy-7-methylcyclopenta[*c*]biphenyl-4'-ol.

The antitumor activities of incargutines A (**1**) and B (**2**) against four tumor cell lines, A549, LOVO, CEM, and MDA-MB-435 (MDA), were determined by the MTT assay [7], with DOX (doxorubicin) as a positive control; the  $IC_{50}$  ( $\mu\text{g/ml}$ ) values are listed in Table 2. Incargutine A (**1**) showed modest cytotoxicities against these four tumor cell lines with  $IC_{50}$  values in the range of 0.47–6.16  $\mu\text{g/ml}$ .

Table 2. Cytotoxicity ( $IC_{50}$  [ $\mu\text{g/ml}$ ]) of Compounds **1** and **2** against A549, LOVO, CEM, and MDA-MB-435 Cell Lines

	A549	LOVO	CEM	MDA
<b>1</b>	3.60	0.47	3.06	6.16
<b>2</b>	13.71	14.59	18.55	4.30
DOX	0.04	0.36	0.01	0.02

This work was supported by the *Program for Changjiang Scholars and Innovative Research Team in University* (PCSIRT), the *NCET Foundation*, the *NSFC* (30725045), the *National 863 Program* (2006AA02Z338), the *China Postdoctoral Science Foundation* (20070410711), the *'973' Program of China* (2007CB507400), the *Shanghai Leading Academic Discipline Project* (B906), and in part by the *Scientific Foundation of Shanghai China* (07DZ19728, 06DZ19717, and 06DZ19005).

### Experimental Part

*General.* TLC: HSG-F<sub>254</sub> silica gel plates (SiO<sub>2</sub>, 10–40 µm; *Yantai Huiyou*, China). Column chromatography (CC): SiO<sub>2</sub> (200–300 mesh; *Yantai Jiangyou*, China); SiO<sub>2</sub> H (10–40 µm; *Qingdao Marine Chemical Ltd.*, China). Optical rotations: *Perkin-Elmer 341* polarimeter; at r.t. IR Spectra: *Bruker FTIR-Vector-22* spectrometer;  $\tilde{\nu}$  in cm<sup>-1</sup>. NMR Spectra: *Bruker Avance<sup>II</sup>-400* spectrometer; in CDCl<sub>3</sub> at 400 (<sup>1</sup>H) and 100 MHz (<sup>13</sup>C);  $\delta$  in ppm, *J* in Hz. ESI-MS: *Varian MAT-212* mass spectrometer; in *m/z*. TOF-ESI-MS: *Q-ToF-micro-YA019* mass spectrometer.

*Plant Material.* The roots of *I. arguta* were collected from Anning, Yunnan Province, P. R. China, in May 2006, and were identified by Prof. *Bao-Kang Huang*, Department of Pharmacognosy, Second Military Medical University. The voucher specimens (LTM20060514) were deposited with the Herbarium of the School of Pharmacy, Shanghai Jiao Tong University, Shanghai, P. R. China.

*Extraction and Isolation.* The dried roots (24.9 kg) of *I. arguta* were chopped and percolated with 80% EtOH (4 × 50 l) at r.t. until the compounds of interest were exhaustively extracted. The solvent was evaporated to give a crude extract (5.2 kg). The extract was suspended in H<sub>2</sub>O (15 l) and the suspension acidified to pH 2 with 20% H<sub>2</sub>SO<sub>4</sub> soln. and filtered. The filtrate was basified to pH 10 with aq. sat. NaHCO<sub>3</sub> soln. and then extracted repeatedly with CHCl<sub>3</sub>. The org. fractions were concentrated to yield the CHCl<sub>3</sub> extract (93 g). The CHCl<sub>3</sub> extract was subjected to CC (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH 1:0 → 10:1): *Fractions 1–14. Fr. 4* (4.5 g) was separated by CC (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH 1:0 → 10:1) and further purified by prep. HPLC (MeOH/H<sub>2</sub>O 65:35): **1** (3.2 mg) and **2** (16.0 mg).

*Incargutine A* (= rel-(3R)-2,3-Dihydro-7-(4-hydroxyphenyl)-3-methyl-1H-inden-4-carboxaldehyde; **1**): Yellow oil.  $[\alpha]_D^{20} = +42.7$  (*c* = 0.15, MeOH). IR (KBr): 3370, 2958, 2867, 1689, 1612, 1591, 1517, 1454, 1382, 1227, 756. <sup>1</sup>H- and <sup>13</sup>C-NMR: *Table 1*. HR-ESI-MS: 251.1074 ( $[M - H]^-$ , C<sub>17</sub>H<sub>15</sub>O<sub>2</sub><sup>-</sup>; calc. 251.1072).

*Incargutine B* (= rel-4-[(1R)-2,3-Dihydro-7-(dimethoxymethyl)-1-methyl-1H-inden-4-yl]phenol; **2**): Yellow oil.  $[\alpha]_D^{20} = +24.5$  (*c* = 0.80, MeOH). IR (KBr): 3375, 2956, 2867, 1612, 1593, 1519, 1454, 1363, 1269, 756. <sup>1</sup>H- and <sup>13</sup>C-NMR: *Table 1*. HR-ESI-MS: 321.1466 ( $[M + Na]^+$ , C<sub>19</sub>H<sub>22</sub>NaO<sub>3</sub><sup>+</sup>; calc. 321.1467).

*Cytotoxicity Assay.* A cytotoxicity assay was carried out according to *Denizot* and *Lang* [7]. Each cell (conc. 1 · 10<sup>4</sup>) was seeded in each well containing 100 µl of DMEM (*Dulbecco's modified Eagle's medium*). Subsequently, various conc. of samples were added. The cells were incubated for 48 h at 37° in an atmosphere containing 5% of CO<sub>2</sub>. Then 10 µl of FBS-free medium (FBS = fetal bovine serum) containing 5 mg/ml of MTT (= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium) soln. was added to the wells. After 4 h of incubation at 37°, the medium was discarded, and the formazan blue formed in the cells was dissolved by adding 100 µl of DMSO. The optical density was measured at 570 nm with a microplate reader (*Molecular Devices Co.*, Menlo Park, CA, USA).

### REFERENCES

- [1] G. D. Li, *Chin. Herb. Med.* **1986**, *17*, 32.
- [2] Y. G. Luo, J. H. Yi, B. G. Li, G. L. Zhang, *Lipids* **2004**, *39*, 907.
- [3] T. F. Ji, X. Z. Feng, *Chin. Tradit. Herb. Drugs* **2002**, *33*, 967.
- [4] Z. W. Yu, H. Y. Zhu, X. S. Yang, Q. Y. Sun, X. J. Hao, *China J. Chin. Mater. Med.* **2005**, *30*, 1335.
- [5] D. Y. Zhou, X. S. Yang, B. Yang, H. Y. Zhu, X. J. Hao, *Nat. Prod. Res. Dev.* **2007**, *19*, 807.
- [6] J. J. Fu, H. Z. Jin, Y. H. Shen, W. D. Zhang, W. Z. Xu, Q. Zeng, S. K. Yan, *Helv. Chim. Acta* **2007**, *90*, 2151.
- [7] F. Denizot, R. Lang, *J. Immunol. Methods* **1986**, *89*, 271.

Received August 4, 2008